AMAG Pharmaceuticals Investor Presentation September 2018

AMAG Pharmaceuticals presented Q2 2018 financial results and strategic updates on its pharmaceutical portfolio including Feraheme, Makena, Intrarosa, and Vyleesi (bremelanotide). The company reported strong revenue growth to $146.3M and announced the sale of its CBR business unit to strengthen its balance sheet. Key developments included FDA acceptance of the Vyleesi NDA with a PDUFA date of March 23, 2019.